Orchid Pharma Ltd (ORCHPHARMA) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Orchid Pharma Ltd reported sales of ₹304.17 Cr, operating profit of ₹14 Cr (OPM 4.6%) and net profit of ₹3.22 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
ORCHPHARMA quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 222.7 217.34 237.48 263.19 193.52 207.27 368.33 304.17 Expenses 192.36 190.97 209.49 268.84 194.99 205.71 338.17 290.17 Operating Profit 30.34 26.37 27.99 -5.65 -1.47 1.56 30.16 14 OPM 13.62% 12.13% 11.79% -2.15% -0.76% 0.75% 8.19% 4.6% Other Income 7.52 8.49 3.9 11.57 10.77 -1.5 7.55 1.83 Interest 3.33 3.8 3.92 2.28 3.73 3.18 1.96 2.23 Depreciation 8.63 8.61 8.87 10.53 8.9 9.03 10.9 10.95 Profit before tax 25.9 22.45 19.1 -6.89 -3.33 -12.15 24.85 2.65 Tax 0% 0% -0.21% 0% 0% 0% 0% 2.64% Net Profit 27.24 20.78 22.29 -5.69 -5.72 -12.61 25.84 3.22 EPS in Rs 5.37 4.1 4.39 -1.12 -1.13 -2.49 5.09 0.63
ORCHPHARMA profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 560 666 819 922 1,233 1,073 Expenses 505 581 708 804 1,199 1,029 Operating Profit 55 84 111 118 34 44 OPM 10% 13% 14% 13% 2.7% 4.1% Other Income 67 52 31 27 29 19 Interest 33 33 17 15 9 11 Depreciation 87 55 33 35 43 40 Profit before tax 2 48 92 96 10 12 Tax 0% 0% -3% 0% -2% - Net Profit -2 46 92 100 10 11 EPS in Rs -0.48 11.35 18.17 19.65 1.96 2.1 Dividend Payout 0% 0% 0% 0% 0% -
ORCHPHARMA balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 41 51 51 51 51 Reserves 648 1,119 1,217 1,223 1,237 Borrowings 331 135 175 282 363 Other Liabilities 205 249 246 167 261 Total Liabilities 1,225 1,554 1,688 1,722 1,911 Fixed Assets 573 620 633 631 692 CWIP 46 31 81 120 341 Investments 44 46 50 49 53 Other Assets 561 857 925 922 826 Total Assets 1,225 1,554 1,688 1,722 1,911
ORCHPHARMA cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 92 18 126 19 101 Cash from Investing Activity 113 -31 -312 -27 -285 Cash from Financing Activity -217 31 167 25 170 Net Cash Flow -11 18 -19 18 -14 Free Cash Flow 238 -8 61 -131 -273 CFO/OP 173% 22% 113% 17% 293%
ORCHPHARMA ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 111 118 87 96 78 Inventory Days 201 217 199 219 111 Days Payable 195 165 173 149 99 Cash Conversion Cycle 117 170 113 166 90 Working Capital Days 97 54 118 135 95 ROCE -2% 5% 9% 8% 2%